Free Trial
NASDAQ:KRON

Kronos Bio Q4 2023 Earnings Report

Kronos Bio logo
$0.72 +0.01 (+1.38%)
Closing price 05/7/2025 03:58 PM Eastern
Extended Trading
$0.72 0.00 (-0.56%)
As of 05/7/2025 05:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kronos Bio EPS Results

Actual EPS
-$0.43
Consensus EPS
-$0.51
Beat/Miss
Beat by +$0.08
One Year Ago EPS
N/A

Kronos Bio Revenue Results

Actual Revenue
$2.29 million
Expected Revenue
$1.50 million
Beat/Miss
Beat by +$790.00 thousand
YoY Revenue Growth
N/A

Kronos Bio Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Wednesday, March 20, 2024
Conference Call Time
7:00PM ET

Upcoming Earnings

Kronos Bio's Q1 2025 earnings is scheduled for Thursday, May 8, 2025, with a conference call scheduled on Wednesday, May 14, 2025 at 6:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Kronos Bio Earnings Headlines

Kronos Bio (KRON) Projected to Post Earnings on Thursday
3..2..1.. AI 2.0 ignition (don’t sleep on this)
I just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring.
Concentra To Acquire Kronos Bio
See More Kronos Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Kronos Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kronos Bio and other key companies, straight to your email.

About Kronos Bio

Kronos Bio (NASDAQ:KRON), a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California.

View Kronos Bio Profile

More Earnings Resources from MarketBeat